GlassScriptPhysician profile
Steven R Klein
NPI 1316917545
$7,768.42
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,203 · 2020: $348 · 2021: $1,250 · 2022: $2,025 · 2023: $1,913 · 2024: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,941.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,665.64 | 2019-2024 | |
| Janssen Biotech, INC. | $983.66 | 2019-2024 | Stelara, Simponi, Remicade |
| Gilead Sciences, INC. | $601.16 | 2019-2024 | |
| Pfizer INC. | $511.72 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $418.31 | 2019-2024 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $297.21 | 2019-2023 | Xifaxan, Plenvu |
| Celgene Corporation | $270.98 | 2021-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $264.28 | 2021-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $238.88 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $195.02 | 2022-2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $187.44 | 2019-2023 | Linzess |
| Merck Sharp & Dohme LLC | $141.40 | 2019-2023 | Dificid |
| Daiichi Sankyo INC. | $128.38 | 2021-2023 | Injectafer |
| Janssen Scientific Affairs, LLC | $123.98 | 2019 | |
| Evoke Pharma, INC. | $103.45 | 2023 | Gimoti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $103.42 | 2023 | Avsola, Amjevita |
| Intercept Pharmaceuticals, INC. | $102.47 | 2020-2024 | Ocaliva |
| Redhill Biopharma INC. | $90.33 | 2021-2023 | Aemcolo, Talicia, Movantik |
| Qol Medical, LLC | $88.14 | 2021-2024 | Sucraid, Sucraid |
| Genzyme Corporation | $79.27 | 2022-2024 | |
| Sandoz INC. | $42.76 | 2023-2024 | Hyrimoz |
| Exact Sciences Corporation | $20.01 | 2023 | Cologuard Collection Kit |
| Stryker Corporation | $19.33 | 2020 | |
| Mylan Institutional INC. | $18.53 | 2023 | Hulio |
| Shire North American Group INC | $15.75 | 2019 | |
| Ardelyx, INC. | $15.08 | 2023 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $14.61 | 2024 | Voquezna |
| Alexion Pharmaceuticals, INC. | $14.05 | 2019 | |
| Endo Pharmaceuticals INC. | $13.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.